— Association to award up to $5 million to platforms globally —
CHICAGO, Oct. 2, 2023 — Today, the Alzheimer’s Association announced the
Global Real-World Data Platforms Program (ALZ-RWD) — a funding program to support the development, expansion and alignment of real-world data globally. The Alzheimer’s Association will award up to $5 million in funding to platforms outside the U.S. for ALZ-RWD. The announcement was made by Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer, during the “Defeating Dementia” conference hosted by the government of the Netherlands in collaboration with the
World Dementia Council.
“Collecting, analyzing and sharing real-world data is essential to ensuring that individuals are accurately diagnosed and treated. For any new treatment approach, real-world experience is critical to understanding long-term effects. It is also essential in the identification and understanding of health disparities that can inform the development and implementation of initiatives to advance health equity,” said Carrillo. “With the launch of this new grant program, we will broaden our global collaboration with partners and scientific leaders across the globe to ensure the success of this new era of treatment.”
In 2022, the Alzheimer’s Association launched the
Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) in the U.S. ALZ-NET is collecting long-term clinical and safety data from patients treated with FDA-approved Alzheimer’s disease therapies in real-world clinical settings. Recipients of ALZ-RWD grant funding will collaborate closely with ALZ-NET.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.